Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Skye Bioscience Inc.

    NASDAQ: SKYE · Real-Time Price · USD
    2.45
    0.30 (13.95%)
    At close: Jun 06, 2025, 3:59 PM
    2.42
    -1.22%
    After-hours: Jun 06, 2025, 05:55 PM EDT

    Skye Bioscience Statistics

    Share Statistics

    Skye Bioscience has 30.98M shares outstanding. The number of shares has increased by 10.36% in one year.

    Shares Outstanding

    n/a
    		 30.98M

    Shares Change (YoY)

    n/a
    		 10.36%

    Shares Change (QoQ)

    n/a
    		 2.1%

    Owned by Institutions (%)

    n/a
    		 69.09%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 6,463

    FTD / Avg. Volume

    n/a
    		 0.92%

    Short Selling Information

    The latest short interest is 3.21M, so 10.37% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.21M

    Short % of Shares Out

    n/a
    		 10.37%

    Short % of Float

    n/a
    		 15.58%

    Short Ratio (days to cover)

    n/a
    		 15.41

    Valuation Ratios

    The PE ratio is -3.89 and the forward PE ratio is -1.49. Skye Bioscience's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -3.89

    Forward PE

    n/a
    		 -1.49

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.52

    P/FCF Ratio

    n/a
    		 -3.85

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Skye Bioscience.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 16.32, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 16.32

    Quick Ratio

    n/a
    		 16.32

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,660,445.19

    Employee Count

    n/a
    		 16

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 10.07K

    Effective Tax Rate

    n/a
    		 -0.04%

    Stock Price Statistics

    The stock price has increased by -77.61% in the last 52 weeks. The beta is 1.67, so Skye Bioscience's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.67

    52-Week Price Change

    n/a
    		 -77.61%

    50-Day Moving Average

    n/a
    		 1.83

    200-Day Moving Average

    n/a
    		 3.37

    Relative Strength Index (RSI)

    n/a
    		 59.11

    Average Volume (20 Days)

    n/a
    		 702,279

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 n/a

    Net Income

    n/a
    		 -26.57M

    EBITDA

    n/a
    		 n/a

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -0.73
    Full Income Statement

    Balance Sheet

    The company has 68.42M in cash and 455.59K in debt, giving a net cash position of 67.96M.

    Cash & Cash Equivalents

    n/a
    		 68.42M

    Total Debt

    n/a
    		 455.59K

    Net Cash

    n/a
    		 67.96M

    Retained Earnings

    n/a
    		 -130.95M

    Total Assets

    n/a
    		 64.79B

    Working Capital

    n/a
    		 57.71B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -25.24M and capital expenditures -1.6M, giving a free cash flow of -26.84M.

    Operating Cash Flow

    n/a
    		 -25.24M

    Capital Expenditures

    n/a
    		 -1.6M

    Free Cash Flow

    n/a
    		 -26.84M

    FCF Per Share

    n/a
    		 -0.74
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    SKYE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SKYE is $15, which is 512.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $15

    Price Target Difference

    n/a
    		 512.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:250.

    Last Split Date

    n/a
    		 Sep 8, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:250

    Scores

    Altman Z-Score

    n/a
    		 -1.99

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist